Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Johns Hopkins Bloomberg School of Public Health University of Alabama at Birmingham University of Minnesota Washington University School of Medicine St. Louis University Long Island Jewish Medical Center North Shore University Hospital Baylor College of Medicine University of Vermont Nemours Children's Clinic University of Florida Indiana University Ohio State University University of Pennsylvania New York University School of Medicine University of Missouri-Columbia Northwestern University Louisiana State University Emory University University of Miami University of South Florida University of California, San Diego National Jewish Health Duke University |
---|---|
Information provided by: | Johns Hopkins Bloomberg School of Public Health |
ClinicalTrials.gov Identifier: | NCT00705341 |
The purpose of this research is to evaluate the methacholine challenge test as an accurate indicator of asthma in patients receiving treatment for asthma. In the first part of the study test results from asthma patients will be compared to those from people who do not have asthma. In the second part of the study, test results for people with asthma on low dose inhaled corticosteroid will be compared to their results on high dose inhaled corticosteroids. Both males and females with stable asthma (asthma participants) and without asthma (controls) may join. Participants will be between 12 and 69 years of age.
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: fluticasone diskus |
Phase IV |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Crossover Assignment, Efficacy Study |
Official Title: | MethaCholine Bronchoprovocation - Influence of High Potency Inhaled corticoSteroids in Asthma (MeCIS) Study |
Estimated Enrollment: | 140 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Low dose: Active Comparator
For people with asthma, fluticasone at 250 mcg per day
|
Drug: fluticasone diskus
Inhaled corticosteroid approved for treatment of asthma
|
High dose: Active Comparator
For people with asthma, fluticasone at 1000 mcg per day
|
Drug: fluticasone diskus
Inhaled corticosteroid approved for treatment of asthma
|
Controls: No Intervention
70 people without asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
|
The study consists of two phases. The first phase is a cross-sectional, case-control study measuring the sensitivity and specificity of methacholine challenge testing for differentiating asthmatic participants from non-asthmatic controls. The second phase is a cross-over, randomized, double-masked trial designed to evaluate the impact of high dose versus low dose inhaled corticosteroids (ICS) on bronchial hyperreactivity (BHR) in asthmatics.
Ages Eligible for Study: | 6 Years to 69 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Asthmatic participants
Inclusion Criteria:
Exclusion Criteria:
Inclusion Criteria:
Exclusion Criteria:
A subject will be excluded if there is a history within the previous 5 yrs of:
Contact: Charlene Levine | 410-614-6022 | clevine@jhsph.edu |
Contact: Ellen Brown, MS | 410-955-3118 | ellbrown@jhsph.edu |
United States, Missouri | |
Washington University School of Medicine | |
St. Louis, Missouri, United States, 631110 | |
United States, Vermont | |
Vermont Lung Center at the University of Vermont | |
Burlington, Vermont, United States, 05405 |
Responsible Party: | Johns Hopkins School of Public Health ( Robert A. Wise, Professor of Medicine ) |
Study ID Numbers: | ALAACRC07 |
Study First Received: | June 24, 2008 |
Last Updated: | August 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00705341 History of Changes |
Health Authority: | United States: Institutional Review Board |
Normal Controls |
Anti-Inflammatory Agents Neurotransmitter Agents Bronchial Diseases Miotics Anti-Asthmatic Agents Asthma Anti-Allergic Agents Cholinergic Agents Lung Diseases, Obstructive |
Hypersensitivity Respiratory Tract Diseases Lung Diseases Methacholine Chloride Hypersensitivity, Immediate Fluticasone Peripheral Nervous System Agents Bronchodilator Agents Respiratory Hypersensitivity |
Anti-Inflammatory Agents Parasympathomimetics Respiratory System Agents Neurotransmitter Agents Bronchial Diseases Cholinergic Agonists Molecular Mechanisms of Pharmacological Action Bronchoconstrictor Agents Physiological Effects of Drugs Cholinergic Agents Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Therapeutic Uses Fluticasone |
Dermatologic Agents Immune System Diseases Miotics Anti-Asthmatic Agents Asthma Anti-Allergic Agents Pharmacologic Actions Autonomic Agents Lung Diseases Methacholine Chloride Hypersensitivity, Immediate Muscarinic Agonists Peripheral Nervous System Agents Bronchodilator Agents Respiratory Hypersensitivity |